96-Well Format-Based Liver–Heart-on-a-Chip Platform for Facile and Parallel Testing of Drug-Induced Cardiotoxicity after Liver Metabolism
- 24 February 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (3) , 636-645
Abstract
Current preclinical drug evaluation predominantly relies on conventional two-dimensional (2D) cell cultures grown in static environments, which lack dynamic interactions and fail to recapitulate complex microenvironments. These approaches are inefficient and overly simplistic, and often require costly animal models that poorly mimic human physiology. Body-on-a-chip (BoC) technology─comprising robust and flexible three-dimensional (3D) microtissues (MTs)─has emerged to address these limitations. BoC platforms constitute microphysiological systems that mimic human organ physiology and function in vitro, enabling improved toxicity screening and personalized medicine. Here, we present a 96–well format-based microfluidic liver–heart-on-a-chip platform that supports parallel, gravity-driven perfusion to efficiently predict and assess multiorgan drug effects. We demonstrate hepatic metabolism of the cardiotoxic prodrug terfenadine (TFND) into its noncardiotoxic metabolite fexofenadine within liver MTs and the consequent physiological–pathological responses of cardiac MTs. The optimized liver–heart-on-a-chip preserves multitissue functionality, underscores the importance of continuous media circulation, and reveals intertissue interactions relevant to drug-induced cardiotoxicity after liver metabolism.Keywords
Funding Information
- Daegu Gyeongbuk Institute of Science and Technology (23-BT-06)
- Daegu Gyeongbuk Institute of Science and Technology (24-NT-01)
- National Research Foundation of Korea (2021M3F7A1082275)
This publication has 31 references indexed in Scilit:
- Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay dataToxicology and Applied Pharmacology, 2022
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological functionBiosensors and Bioelectronics, 2021
- High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening ModelStem Cell Reviews and Reports, 2017
- Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modelingDrug Discovery Today, 2016
- 3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysisJournal of Biotechnology, 2015
- Designing Prodrugs and Bioprecursors2015
- How multi-organ microdevices can help foster drug developmentAdvanced Drug Delivery Reviews, 2014
- The future of drug safety testing: expanding the view and narrowing the focusDrug Discovery Today, 2009
- Gravity‐induced convective flow in microfluidic systems: Electrochemical characterization and application to enzyme‐linked immunosorbent assay testsElectrophoresis, 2004